HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Inhibikase Therapeutics in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.10) for the quarter, up from their previous forecast of ($0.12). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.59) EPS.

IKT has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, January 22nd. Bank of America began coverage on Inhibikase Therapeutics in a research note on Wednesday, January 21st. They issued a “buy” rating and a $6.00 price objective on the stock. Cantor Fitzgerald began coverage on Inhibikase Therapeutics in a research report on Thursday, December 11th. They set an “overweight” rating and a $4.00 price objective for the company. LADENBURG THALM/SH SH began coverage on Inhibikase Therapeutics in a research note on Wednesday, March 4th. They set a “buy” rating and a $4.00 target price for the company. Finally, Lifesci Capital raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Four investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Inhibikase Therapeutics has a consensus rating of “Buy” and a consensus price target of $5.50.

Inhibikase Therapeutics Price Performance

Shares of IKT opened at $1.81 on Wednesday. The company has a market capitalization of $136.08 million, a PE ratio of -3.77 and a beta of 0.86. Inhibikase Therapeutics has a one year low of $1.33 and a one year high of $2.37. The company’s fifty day moving average price is $1.78 and its 200 day moving average price is $1.68.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Siren L.L.C. acquired a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at about $11,992,000. Squadron Capital Management LLC acquired a new stake in Inhibikase Therapeutics during the fourth quarter worth about $8,661,000. Spruce Street Capital LP acquired a new stake in Inhibikase Therapeutics during the fourth quarter worth about $7,342,000. ADAR1 Capital Management LLC increased its stake in Inhibikase Therapeutics by 53.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after acquiring an additional 2,816,346 shares during the period. Finally, Sands Capital Alternatives LLC increased its stake in Inhibikase Therapeutics by 18.9% during the fourth quarter. Sands Capital Alternatives LLC now owns 13,018,965 shares of the company’s stock valued at $26,689,000 after acquiring an additional 2,068,965 shares during the period. Institutional investors own 3.81% of the company’s stock.

Key Inhibikase Therapeutics News

Here are the key news stories impacting Inhibikase Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term EPS forecasts for 2026 (Q1–Q3 2026) and increased its FY2026 estimate to ($0.47) from ($0.52), signaling smaller expected losses next year — a catalyst for buying interest. HC Wainwright raises FY2026 estimate
• Positive Sentiment: HC Wainwright reiterated a “Strong‑Buy” rating while publishing detailed quarterly estimates for 2026–2027 (Q1–Q4 2026/2027 and FY2027), which reinforces analyst conviction and likely supports investor demand. HC Wainwright reiterates Strong‑Buy
• Neutral Sentiment: Despite the upward revisions, HC Wainwright’s published numbers still show Inhibikase operating at a loss through 2027 (FY2027 EPS ~ ($0.59)), highlighting that the company remains pre‑profit and progress will depend on clinical/regulatory milestones and cash runway. HC Wainwright FY2027 outlook

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.